<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2304-0106</journal-id>
<journal-title><![CDATA[Anales de la Academia de Ciencias de Cuba]]></journal-title>
<abbrev-journal-title><![CDATA[Anales de la ACC]]></abbrev-journal-title>
<issn>2304-0106</issn>
<publisher>
<publisher-name><![CDATA[Academia de Ciencias de Cuba]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2304-01062021000100028</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Autoanticuerpos para diagnóstico y pronóstico en artritis reumatoide: inmunoensayo cubano con péptido citrulinado del fibrinógeno]]></article-title>
<article-title xml:lang="en"><![CDATA[Autoantibodies for diagnostic and prognostic in rheumatoid arthritis: Cuban immunoassay with citrullinated fibrinogen peptide]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Téllez]]></surname>
<given-names><![CDATA[Goitybell]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Rives]]></surname>
<given-names><![CDATA[Bárbara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[Vicky]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martiatu Hendrich]]></surname>
<given-names><![CDATA[Maité]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Pelier]]></surname>
<given-names><![CDATA[Cira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Nacional de Genética Médica  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>11</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2304-01062021000100028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2304-01062021000100028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2304-01062021000100028&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La artritis reumatoide (AR) es una enfermedad inflamatoria crónica que se caracteriza por la presencia de autoanticuerpos. Objetivo: desarrollar inmunoensayos cubanos para determinar anticuerpos y evaluar la utilidad de anticuerpos contra un péptido del fibrinógeno citrulinado para diagnóstico y valoración clínico terapéutica de pacientes con AR.  Métodos:  Se realizó un estudio de casos y controles. Participaron 162 pacientes con AR, 112 pacientes con otras enfermedades y 50 individuos sanos. Se evaluó el desempeño analítico y diagnóstico de un inmunoensayo novedoso para determinar anticuerpos contra un péptido del fibrinógeno citrulinado diseñado mediante informática, de factor reumatoide y anticuerpos antiqueratina. Se determinaron mediante inmunoensayos comerciales los anticuerpos factor reumatoide, antipéptidos citrulinados de segunda generación, anti vimentina citrulinada mutada, anti vimentina carbamilada y antiqueratina. Se realizó un estudio longitudinal con 60 pacientes con AR temprana. Se determinaron los anticuerpos, proteína C reactiva, velocidad de sedimentación globular, índice de actividad y respuesta al metotrexato a los seis meses.  Resultados:  Se introdujeron en la práctica 3 inmunoensayos. El desempeño diagnóstico de los anticuerpos contra el péptido del fibrinógeno citrulinado fue superior a los inmunoensayos comerciales más utilizados, con un costo por paciente inferior (5,52 CUC) a los anticuerpos de segunda generación (14,00 CUC). Los pacientes con estos anticuerpos, tuvieron mayor riesgo para mayor actividad (riesgo=0,96; p=0,0424) y baja respuesta al tratamiento (riesgo = 0,82; p = 0,0402). La determinación de anticuerpos contra un péptido novedoso del fibrinógeno citrulinado tiene menor costo y gran utilidad para el diagnóstico y evaluación clínico terapéutica en la AR.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Rheumatoid arthritis (RA) is a chronic and inflammatory disease characterized by presence of autoantibodies. Objective: to develop Cuban immunoassays to determine antibodies and evaluate the usefulness of antibodies against a citrullinated fibrinogen peptide for diagnosis and therapeutic clinical assessment of patients with RA.  Methods:  A case-control study was conducted. Participants were 162 patients with RA, 112 patients with other diseases and 50 healthy individuals. The analytical and diagnostic performance of a novel immunoassay was evaluated to determine antibodies against a citrullinated fibrinogen peptide designed by computer, rheumatoid factor and antiqueratin antibodies. Commercial rheumatoid factor antibodies, second generation citrullinated peptides, mutated citrullinated vimentin, carbamylated vimentin and antiqueratin were determined by commercial immunoassays. A longitudinal study was conducted on 60 patients with early RA. Antibodies, C-reactive protein, erythrocyte sedimentation rate, activity index and response to methotrexate after six months were determined.  Results:  Three immunoassays were introduced into practice. The diagnostic performance of the antibodies against the citrullinated fibrinogen peptide was superior to the most commonly used commercial immunoassays, with a lower cost per patient (5,52 CUC) than the second-generation antibodies (14,00 CUC). Patients with these antibodies had a higher risk for greater activity (risk = 0,96; p = 0,0424) and low response to treatment (risk = 0,82; p = 0,0402). The determination of antibodies against a novel citrullinated fibrinogen peptide has lower cost and great utility for the diagnosis and therapeutic clinical evaluation in RA.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos contra péptidos citrulinados]]></kwd>
<kwd lng="es"><![CDATA[fibrinógeno]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[antibodies against citrullinated peptides]]></kwd>
<kwd lng="en"><![CDATA[fibrinogen]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Immunología Celular y Molecular]]></source>
<year>2015</year>
<edition>8va</edition>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Elseiver Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiology of rheumatoid arthritis: A historical and evidence-based perspective]]></article-title>
<source><![CDATA[Clinical Management of the Rheumatoid Hand, Wrist, and Elbow]]></source>
<year>2016</year>
<page-range>13-9</page-range><publisher-loc><![CDATA[Springer International Publishing ]]></publisher-loc>
<publisher-name><![CDATA[Switzerland]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trouw]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rispens]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Toes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond citrullination other post-translational protein modifications in rheumatoid arthritis]]></article-title>
<source><![CDATA[Nature Reviews/rheumatology]]></source>
<year>2017</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>331-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cantora]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Artritis reumatoide temprana resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>148-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sokolove]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lahey]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bengtsson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Saevarsdottir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alfredsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of anticitrullinated protein antibody reactivity in a subset of anti-CCP-negative rheumatoid arthritis association with cigarette smoking and HLA-DRB1 'shared epitope' alleles]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2015</year>
<volume>74</volume>
<page-range>579-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yarwood]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Huizinga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Worthington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The genetics of rheumatoid arthritis risk and protection in different stages of the evolution of RA]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2016</year>
<volume>55</volume>
<page-range>199-209</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnett]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Bloch]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revised criteria for the classification of Rheumatoid Arthritis]]></article-title>
<collab>The American Rheumatism association 1987</collab>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1988</year>
<volume>31</volume>
<page-range>315-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romana]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pecani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Alessandri]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valesini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-translational modifications in rheumatoid arthritis and atherosclerosis Focus on citrullination and carbamylation]]></article-title>
<source><![CDATA[Journal of International Medical Research]]></source>
<year>2016</year>
<volume>44</volume>
<page-range>81-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aletaha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Neogi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Silman]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Funovits]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Felson]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Bingham]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis classification criteria an American College of Rheumatology/European League Against Rheumatism collaborative initiative]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2010</year>
<volume>62</volume>
<page-range>2569-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bos]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Van de Stadt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sohrabian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rönnelid]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van Schaardenburg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of anti-citrullinated protein antibody and rheumatoid factor isotypes prior to the onset of rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Research &amp; Therapy]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>405</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Toscano]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Olivas-Flores]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Zavaleta-uñiz]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Gamez-Nava]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Muñoz]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce-Guarneros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-. generation of anticitrullinated cyclic peptides testing]]></article-title>
<source><![CDATA[Biomed Res Intl]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rincon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Battafarano]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Escalante]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality in Rheumatoid Arthritis (RA) factors associated with recording RA on death certificates]]></article-title>
<source><![CDATA[BMC Musculoskeletal Disorders]]></source>
<year>2015</year>
<volume>16</volume>
<page-range>277-83</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ossipova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cerqueira]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kharlamova]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Israelsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Holmdahl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint]]></article-title>
<source><![CDATA[Arthritis Research &amp; Therapy]]></source>
<year>2014</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arana]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ku]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Canul]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chan Zapata]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importancia clínica de los anticuerpos péptidos cíclicos citrulinados en el diagnóstico de la artritis reumatoide]]></article-title>
<source><![CDATA[ReIbCi]]></source>
<year>2015</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ospelt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Feist]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Camici]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>0</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chatzidionysiou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs 2016 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>960-77</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prevoo]]></surname>
<given-names><![CDATA[MLL]]></given-names>
</name>
<name>
<surname><![CDATA[Van't Hof]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuper]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Van Leeuwen]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Van de Putte]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Van Riel]]></surname>
<given-names><![CDATA[PLCM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modified disease activity scores that include twentyeight- joint counts]]></article-title>
<source><![CDATA[Arthritis rheum]]></source>
<year>1995</year>
<volume>38</volume>
<page-range>44-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la calidad de vida relacionada con la salud en pacientes con artritis reumatoide en el Centro de Reumatología]]></article-title>
<source><![CDATA[Rev Cuba Reumatol]]></source>
<year>2015</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>CECMED</collab>
<source><![CDATA[Requisitos para la evaluación del desempeño de los diagnosticadores. Regulación 47-2007]]></source>
<year>2007</year>
<publisher-name><![CDATA[Centro para el control de la calidad de los medicamentos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>CECMED</collab>
<source><![CDATA[Requisitos para la autorización de comercialización de diagnosticadores. Regulación D-08-13]]></source>
<year>2013</year>
<publisher-name><![CDATA[Centro para el control de la calidad de los medicamentos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa Azze]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<source><![CDATA[Bases Metodológicas para la evaluación de anticuerpos en ensayos clínicos de vacunas mediante técnicas inmunoenzimáticas]]></source>
<year>2004</year>
<edition>1</edition>
<publisher-loc><![CDATA[Ciudad de La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Finlay]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blachère]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Parveen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Orange]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory but not apoptotic death of granulocytes citrullinates fibrinogen]]></article-title>
<source><![CDATA[Arthritis Research &amp; Therapy]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>369-76</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornillet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sebbag]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verrouil]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Magyar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Babos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ruyssen-Witrand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The fibrin-derived citrullinated peptide ß60-74Cit60,72,74 bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2014</year>
<volume>61</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>117-25</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicaise-Roland]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nogueira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Demattei]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies to citrullinated fibrinogen comparedwith anti-MCVand anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage data fromthe French ESPOIR cohort]]></article-title>
<source><![CDATA[Annals of the Rheumatic Diseases]]></source>
<year>2013</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>357-62</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Lopez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha-Muñoz]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce-Guarneros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Chavez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar-Paramo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis]]></article-title>
<source><![CDATA[J Immunol Res]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fountai]]></surname>
</name>
<name>
<surname><![CDATA[DL]]></surname>
</name>
<name>
<surname><![CDATA[Cadwell]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Madrigal]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Poorafshar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The performance of anti-cyclic citrullinated peptide assays in diagnosing rheumatoid arthritis a systematic review and meta-analysis. Clinical and Experimin diagnosing rheumatoid arthritis: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clinical and Experimental Rheumatology]]></source>
<year>2018</year>
<volume>36</volume>
<page-range>144-52</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-Grajales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Vahos]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Betancur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Gómez]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuencia de anticuerpos antipéptido cíclico citrulinado y factor reumatoide en pacientes con enfermedades reumatológicas de un centro de reumatología, Medellín, Colombia]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2014</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>177-82</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huizinga]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Toes]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pathogenic potential of autoreactive antibodies in rheumatoid arthritis]]></article-title>
<source><![CDATA[Semin Immunopathol]]></source>
<year>2014</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>313-25</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jay]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Efthimiou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology: Research and Reviews]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>67-79</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janssen]]></surname>
<given-names><![CDATA[KMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Westra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chalan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Boots]]></surname>
<given-names><![CDATA[AMH]]></given-names>
</name>
<name>
<surname><![CDATA[De Smit]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Winkelhoff]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulatory CD4+ T-cell subsets and anti-citrullinated protein antibody repertoire potential biomarkers for arthritis development in seropositive arthralgia patients?]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2016</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Breedveld]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs 2013 update]]></article-title>
<source><![CDATA[AnnRheum Dis]]></source>
<year>2014</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>492-509</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joshua]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schobers]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Titcombe]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Israelsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rönnelid]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells]]></article-title>
<source><![CDATA[Arthritis Research &amp; Therapy]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>284-93</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
